These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28056160)

  • 1. Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library.
    Cuozzo JW; Centrella PA; Gikunju D; Habeshian S; Hupp CD; Keefe AD; Sigel EA; Soutter HH; Thomson HA; Zhang Y; Clark MA
    Chembiochem; 2017 May; 18(9):864-871. PubMed ID: 28056160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
    Zuo Y; Shi Y; Li X; Teng Y; Pan Z
    Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
    Asami T; Kawahata W; Sawa M
    Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Aug; 23(15):4344-4353. PubMed ID: 26169764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
    Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
    Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
    Xing L; Huang A
    Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
    Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
    J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry.
    Guilinger JP; Archna A; Augustin M; Bergmann A; Centrella PA; Clark MA; Cuozzo JW; Däther M; Guié MA; Habeshian S; Kiefersauer R; Krapp S; Lammens A; Lercher L; Liu J; Liu Y; Maskos K; Mrosek M; Pflügler K; Siegert M; Thomson HA; Tian X; Zhang Y; Konz Makino DL; Keefe AD
    Bioorg Med Chem; 2021 Jul; 42():116223. PubMed ID: 34091303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Xin M; Zhao X; Huang W; Jin Q; Wu G; Wang Y; Tang F; Xiang H
    Bioorg Med Chem; 2015 Oct; 23(19):6250-7. PubMed ID: 26344595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
    Shi Q; Tebben A; Dyckman AJ; Li H; Liu C; Lin J; Spergel S; Burke JR; McIntyre KW; Olini GC; Strnad J; Surti N; Muckelbauer JK; Chang C; An Y; Cheng L; Ruan Q; Leftheris K; Carter PH; Tino J; De Lucca GV
    Bioorg Med Chem Lett; 2014 May; 24(9):2206-11. PubMed ID: 24685542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
    Bavi R; Kumar R; Choi L; Woo Lee K
    PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation.
    Lopez-Tapia F; Lou Y; Brotherton-Pleiss C; Kuglstatter A; So SS; Kondru R
    Bioorg Med Chem Lett; 2019 May; 29(9):1074-1078. PubMed ID: 30857747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.
    Wang B; Deng Y; Chen Y; Yu K; Wang A; Liang Q; Wang W; Chen C; Wu H; Hu C; Miao W; Hur W; Wang W; Hu Z; Weisberg EL; Wang J; Ren T; Wang Y; Gray NS; Liu Q; Liu J
    Eur J Med Chem; 2017 Sep; 137():545-557. PubMed ID: 28628824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S; Habeeb SKM
    J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a Substrate-Mediated Selection with c-Src Tyrosine Kinase to a DNA-Encoded Chemical Library.
    Kim D; Sun Y; Xie D; Denton KE; Chen H; Lin H; Wendt MK; Post CB; Krusemark CJ
    Molecules; 2019 Jul; 24(15):. PubMed ID: 31366048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.
    Young WB; Barbosa J; Blomgren P; Bremer MC; Crawford JJ; Dambach D; Gallion S; Hymowitz SG; Kropf JE; Lee SH; Liu L; Lubach JW; Macaluso J; Maciejewski P; Maurer B; Mitchell SA; Ortwine DF; Di Paolo J; Reif K; Scheerens H; Schmitt A; Sowell CG; Wang X; Wong H; Xiong JM; Xu J; Zhao Z; Currie KS
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1333-7. PubMed ID: 25701252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.